R. David Dantzker's most recent trade in Surmodics, Inc. was a trade of 5,275 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,275 | 0 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.30 per share. | 13 Feb 2025 | 5,275 | 44,399 (0%) | 0% | 27.3 | 144,008 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.16 per share. | 13 Feb 2025 | 4,216 | 40,183 (0%) | 0% | 34.2 | 144,019 | Common Stock |
Surmodics, Inc. | R. David Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 3,853 | 3,853 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | Dantzker David R. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 1,803 | 39,124 (0%) | 0% | 0 | Common Stock | |
Surmodics, Inc. | Dantzker David R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.95 per share. | 19 Jan 2024 | 3,932 | 40,094 (0%) | 0% | 23.9 | 94,171 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2024 | 3,932 | 0 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | Dantzker David R. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.97 per share. | 19 Jan 2024 | 2,773 | 37,321 (0%) | 0% | 34.0 | 94,199 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 4,674 | 4,674 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 1,984 | 36,162 (0%) | 0% | 0 | Common Stock | |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.18 per share. | 14 Nov 2022 | 4,366 | 36,951 (0%) | 0% | 20.2 | 88,106 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2022 | 4,366 | 0 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 14 Nov 2022 | 2,773 | 34,178 (0%) | 0% | 33.0 | 91,507 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 3,555 | 3,555 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 1,375 | 32,585 (0%) | 0% | 0 | Common Stock | |
Surmodics, Inc. | David R. Dantzker | Director | Sale of securities on an exchange or to another person at price $ 47.01 per share. | 24 Nov 2021 | 3,475 | 30,821 (0%) | 0% | 47.0 | 163,360 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2021 | 5,576 | 0 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.31 per share. | 03 Nov 2021 | 5,576 | 36,397 (0%) | 0% | 21.3 | 118,825 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.56 per share. | 03 Nov 2021 | 2,101 | 34,296 (0%) | 0% | 56.6 | 118,833 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 55.60 per share. | 30 Sep 2021 | 337 | 30,821 (0%) | 0% | 55.6 | 18,737 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 54.25 per share. | 30 Jun 2021 | 345 | 30,484 (0%) | 0% | 54.2 | 18,716 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 56.07 per share. | 31 Mar 2021 | 334 | 30,139 (0%) | 0% | 56.1 | 18,727 | Common Stock |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 2,964 | 2,964 | - | - | Stock Option (right to buy) | |
Surmodics, Inc. | David R. Dantzker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 1,067 | 29,805 (0%) | 0% | 0 | Common Stock |